These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20029466)

  • 1. Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia.
    Sidhom I; Shaaban K; Soliman S; Ezzat S; El-Anwar W; Hamdy N; Yassin D; Salem S; Hassanein H; Mansour MT
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):111-20. PubMed ID: 20029466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunophenotyping characteristics of T-cell acute lymphoblastic leukemia].
    Chen LJ; Li JY; Wu YJ; Yang H; Qian SX; Wu HX; Lu H; Xu W; Sheng RL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):692-5. PubMed ID: 17708784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party.
    Hann IM; Richards SM; Eden OB; Hill FG
    Leukemia; 1998 Aug; 12(8):1249-55. PubMed ID: 9697880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Khogeer H; Rahman H; Jain N; Angelova EA; Yang H; Quesada A; Ok CY; Sui D; Wei P; Al Fattani A; Pierce S; Loghavi S; Lamb A; Hu P; Thakral B; Kanagal-Shamanna R; Jorgensen JL; Jabbour EJ; Kantarjian HM; Medeiros LJ; Khoury JD
    Br J Haematol; 2019 Aug; 186(4):538-548. PubMed ID: 31115909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotyping parameters as prognostic factors in T-acute leukemia patients.
    Babusikova O; Stevulova L; Fajtova M
    Neoplasma; 2009; 56(6):508-13. PubMed ID: 19728759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukemia: A study from Northern India.
    Sharma M; Sachdeva MU; Varma N; Varma S; Marwaha RK
    J Cancer Res Ther; 2016; 12(2):620-6. PubMed ID: 27461621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
    Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
    Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
    Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients.
    Liao H; Lai H; Chen J; Shuai X; Zhang X; Yang Y; Lyu M; Zheng Q
    Cancer Med; 2023 Apr; 12(8):9615-9626. PubMed ID: 36951610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics of T-cell lineage immunophenotype in 95 patients with acute lymphoid leukemia].
    Yuan TT; Liu YR; Chang Y; Hao L; Wang YZ; Jiang B; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1134-40. PubMed ID: 22040958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.
    Fuhrmann S; Schabath R; Möricke A; Zimmermann M; Kunz JB; Kulozik AE; Ludwig WD; Schrappe M; Karawajew L; Ratei R
    Br J Haematol; 2018 Oct; 183(1):96-103. PubMed ID: 30028023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
    Zhao F; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
    Xia M; Zhang H; Lu Z; Gao Y; Liao X; Li H
    J Pediatr Hematol Oncol; 2016 Aug; 38(6):418-22. PubMed ID: 27438018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34 is not Expressed by Blasts in a Third of B-ALL Patients and its Negativity is associated with Aberrant Marker Expression: A Retrospective Analysis.
    Garg N; Gupta R; Kotru M
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):919-925. PubMed ID: 33773558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.